Clinical trials
First Line Therapy clinical trials
Below are recruiting first line therapy clinical trials, each written for real people, not researchers. We’re tracking 455 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04638790RecruitingPhase 3
First treatment chemotherapy study for newly diagnosed Hodgkin lymphoma
This trial studies the best first chemotherapy approach for people newly diagnosed with classical Hodgkin lymphoma. It may help improve outcomes by comparing how treatment is given in routine care settings in Russia.
Mumbai, Opd-81 Main Building, Dr. E Borges Road, Parel 400012Ages 18–50 - NCT04722978RecruitingPhase 3
Chemo plus moxifloxacin for metastatic triple-negative breast cancer
This trial tests whether adding moxifloxacin (an antibiotic) to standard chemotherapy helps people with metastatic triple-negative breast cancer live longer or respond better. You may qualify if your cancer has the right lab markers and you haven’t had treatment for metastatic disease yet.
Guangzhou, GuangdongAges 18–70 - NCT04834544RecruitingPhase 2
Maintenance vaccine treatment after first chemotherapy for ovarian cancer
This Phase 2 trial studies a maintenance vaccine (DCVAC/OvCa) given after standard first-line chemotherapy and surgery for certain advanced ovarian cancers. It aims to help keep the cancer from coming back for longer by boosting the body’s anti-cancer response.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05007132RecruitingPhase 2
First-line metastatic colon or rectal cancer study with targeted drugs
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
BerlinAges 18 years+ - NCT05085028RecruitingPhase 3
Lower-dose pembrolizumab for lung cancer after 6 months
This trial studies whether giving pembrolizumab less often can work just as well for advanced non-small cell lung cancer after you’ve already had 6 months of treatment and are still benefiting. It may help reduce how often you need treatment while keeping cancer control.
BournemouthAges 18 years+ - NCT05188859RecruitingPhase 2
Testing sintilimab, anlotinib, and chemo for pleural mesothelioma
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
Taiyuan, ShanxiAges 18 years+ - NCT05218889RecruitingPhase 1/Phase 2
Surufatinib plus immunotherapy for advanced pancreatic cancer
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
BeijingAges 18–75 - NCT05260671RecruitingPhase 2
Penpulimab plus cetuximab for advanced head and neck cancer
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
Changchun, JilinAges 18–80 - NCT05271916RecruitingPhase 1/Phase 2
New targeted drugs for advanced lung cancer with EGFR L858R
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05286619RecruitingPhase 2
Pembrolizumab with chemotherapy for recurrent head and neck cancer
This trial studies whether pembrolizumab plus chemotherapy (platinum and gemcitabine) can control recurrent or metastatic head and neck squamous cell carcinoma that can’t be cured with local treatments. It may help shrink tumors and slow disease growth in people who haven’t had cancer medicines for this stage before.
Kuala LumpurAges 18 years+ - NCT05299840Recruiting
Test a device to choose the first chemo for metastatic colon cancer
This study tests whether using the Oncogramme® device to guide the first-line treatment improves care for people with metastatic colorectal (colon/rectum) cancer. If the device helps pick the most suitable standard chemotherapy plan, it could lead to better outcomes than choosing without it.
MarseilleAges 18 years+ - NCT05302284RecruitingPhase 3
Testing RC48-ADC plus toripalimab for first-time urothelial cancer
This trial tests whether RC48-ADC combined with toripalimab works better as the first treatment for urothelial cancer that cannot be removed by surgery or has spread. It may help shrink tumors and improve outcomes in people whose cancer has the right HER2 and other eligibility features.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05379803RecruitingPhase 2
High-dose furmonertinib for lung cancer with brain metastases
This trial tests a high-dose targeted pill, furmonertinib, in people with EGFR-mutated non-small cell lung cancer that has spread to the brain. It aims to better control both the lung cancer and the brain metastases by targeting a specific gene change.
Changsha, HunanAges 18 years+ - NCT05442060RecruitingPhase 2
Test medicine add-on to erlotinib for EGFR lung cancer
This Phase 2 trial tests whether adding OBI-833/OBI-821 to the standard targeted pill erlotinib works better for some people with EGFR-mutated lung cancer. It may help shrink tumors that already started responding to erlotinib.
Taipei, Beitou DistrictAges 20 years+ - NCT05475366Recruiting
Choosing the right first chemotherapy for advanced pancreatic cancer
This trial tests a personalized approach to selecting your first chemotherapy based on tumor gene activity. It aims to match treatment to your cancer’s biology to improve outcomes for people with advanced (metastatic) pancreatic cancer.
ClichyAges 18–75 - NCT05580861RecruitingPhase 1/Phase 2
Sulfasalazine for newly diagnosed AML in older adults on chemo
This Phase 1/2 trial studies whether sulfasalazine, added to intensive chemotherapy, can help older adults with newly diagnosed acute myeloid leukemia (AML). It aims to improve treatment effectiveness and track leukemia “leftover cells” in some participants.
AmiensAges 60 years+ - NCT05594927RecruitingPhase 3
Test icaritin vs huachansu for advanced liver cancer with poor health
This Phase 3 trial compares two medicines—icaritin soft capsules versus huachansu tablets—as first treatment for unresectable hepatocellular carcinoma (HCC) that has “poor prognosis” blood test markers. It aims to see which option works better and is safer for people who can’t use standard first-line treatments or don’t want them.
Nanchang, JiangxiAges 18 years+ - NCT05598528Recruiting
Study why some lung cancers don’t respond to EGFR pills
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
Changsha, HunanAges 18 years+ - NCT05733598RecruitingPhase 2
RP2 plus standard treatment for advanced liver or bile cancers
This Phase 2 trial studies whether RP2, added to standard second-line treatment, can improve outcomes for people with advanced liver cancer or bile duct/gallbladder cancer. It may help by training the immune system to better attack the cancer after the cancer has already grown despite prior treatment.
Beverly Hills, CaliforniaAges 18 years+ - NCT05744687RecruitingPhase 2/Phase 3
Letrozole plus SPH4336 versus letrozole alone for breast cancer
This study tests whether adding SPH4336 to letrozole works better than letrozole plus a placebo for treating hormone-receptor–positive, HER2-negative breast cancer in people starting first-line treatment. It may help slow cancer growth more effectively if the added drug is beneficial.
Fuzhou, FujianAges 18–75 - NCT05751018RecruitingPhase 2
Pyrotinib for first treatment of HER2-mutated lung cancer
This Phase 2 trial studies pyrotinib as a first (initial) anti-cancer treatment for advanced lung cancer that has specific HER2 changes. It aims to shrink tumors and control the cancer, especially in people whose test results show HER2 insertion mutation, point mutation, or amplification.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05757336RecruitingPhase 2
Study drug mix for unresectable gallbladder cancer
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
ShanghaiAges 18–75 - NCT05760378RecruitingPhase 3
Famitinib plus immunotherapy for advanced triple-negative breast cancer
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05765084RecruitingPhase 1/Phase 2
Atezolizumab plus WT1 vaccine with chemo for pleural mesothelioma
This trial studies a treatment plan that combines an immune drug (atezolizumab) and a personalized cancer vaccine (WT1/DC) with standard first-line chemotherapy for epithelioid malignant pleural mesothelioma that cannot be removed with surgery. It aims to improve control of the cancer by helping the immune system work alongside chemotherapy.
Edegem, AntwerpAges 18 years+
Hear when a new First Line Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first line therapy?
- Yes. Clin2 currently lists 455 recruiting first line therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first line therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first line therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.